ストックスクリーナーアプリを入手
5.19
0.95%
-0.05
アフターアワーズ：
5.19
前日終値:
$5.24
開ける：
$5.25
24時間の取引高:
2.22M
Relative Volume:
0.79
時価総額：
$773.60M
収益：
-
当期純損益:
$-134.24M
株価収益率:
-2.9322
EPS:
-1.77
ネットキャッシュフロー:
$-121.34M
1週間 パフォーマンス:
-7.82%
1か月 パフォーマンス:
-6.65%
6か月 パフォーマンス:
+112.70%
1年 パフォーマンス:
+73.00%
1日の値動き範囲:
$5.13
$5.435
1週間の範囲:
$5.09
$5.855
52週間の値動き範囲:
$1.285
$7.18
Annexon Inc Stock (ANNX) Company Profile
Compare ANNX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.19 | 781.05M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-23 | 開始されました | Chardan Capital Markets | Buy |
| 2024-03-01 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-10-30 | 開始されました | Wells Fargo | Overweight |
| 2023-05-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-05-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 開始されました | Jefferies | Buy |
| 2022-09-09 | 開始されました | BTIG Research | Buy |
| 2021-11-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-09-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | BofA Securities | Buy |
| 2020-08-18 | 開始されました | Cowen | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
すべてを表示
Annexon Inc (ANNX) 最新ニュース
FMR LLC Reduces Stake in Annexon Inc: A Strategic Portfolio Adju - GuruFocus
Aug Decliners: What are the risks of holding Annexon IncJuly 2025 WrapUp & Safe Swing Trade Setup Alerts - baoquankhu1.vn
A Pivotal Year Ahead for Annexon’s Clinical Ambitions - AD HOC NEWS
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Macro Review: Is Annexon Inc in a bullish channel2025 Price Targets & Low Drawdown Momentum Ideas - baoquankhu1.vn
Dow Update: Can Annexon Inc reach all time highs this yearIPO Watch & Growth Focused Stock Reports - baoquankhu1.vn
Market Recap: Will Annexon Inc benefit from government policyJuly 2025 Reactions & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Breakout Watch: Will Annexon Inc benefit from government policyDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Buy Signal: Does Annexon Inc meet Warren Buffetts criteria2025 Big Picture & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Annexon, Inc. $ANNX Stake Cut by J. Safra Sarasin Holding AG - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Annexon Biosciences (ANNX) - The Globe and Mail
Investment Recap: Can HSCS sustain its profitability2025 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
Analyst Downgrade: Will Annexon Inc stock benefit from M AJuly 2025 PostEarnings & Real-Time Volume Triggers - baoquankhu1.vn
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases - Seeking Alpha
Annexon stock hits 52-week high at 7.1 USD By Investing.com - Investing.com Nigeria
Annexon stock hits 52-week high at 7.1 USD - Investing.com
Support Test: What are the risks of holding Annexon IncQuarterly Risk Review & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Annexon (NASDAQ:ANNX) Hits New 12-Month HighHere's Why - MarketBeat
Annexon Inc (NASDAQ:ANNX) Advances Complement Biology Platform - Kalkine Media
Annexon (NASDAQ:ANNX) Stock Price Up 9.5%Still a Buy? - MarketBeat
Aug Chart Watch: What are the risks of holding Annexon IncMarket Sentiment Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Does Annexon’s EMA Filing For Tanruprubart Reshape The Bull Case For ANNX? - Yahoo Finance
Annexon (ANNX) Is Up 15.6% After EMA Filing For GBS Antibody Tanruprubart Has The Bull Case Changed? - simplywall.st
Levels Update: Will Annexon Inc benefit from government policyWeekly Investment Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome - Yahoo Finance
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon (NASDAQ:ANNX) Trading Down 5.9%Here's Why - MarketBeat
Key facts: Annexon to Submit FDA Application for Dry AMD Treatment; Key Milestones Expected in 2026 - TradingView
Alpha Buying: Managing Biotech Risk With Insider Clues - Benzinga
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead - MarketBeat
Annexon, Inc. Updates on Strategic Developments and Product Pipeline - TradingView
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Annexon Biosciences stock rating reiterated by Cantor Fitzgerald - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Amgen (AMGN) and Annexon Biosciences (ANNX) - The Globe and Mail
Annexon (NASDAQ:ANNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Pharma News: Will Annexon Inc. stock benefit from AI adoptionWeekly Market Report & Weekly Chart Analysis and Guides - Bộ Nội Vụ
Hedge Fund and Insider Trading News: Ray Dalio, Chris Rokos, Steven Cohen, Bill Ackman, Israel Englander, Scott Bessent, Citadel Investment Group, Eisler Capital, Virco Mfg Corp (VIRC), Annexon Inc (ANNX), and More - Insider Monkey
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 - The Manila Times
Annexon Accelerating Next Generation Targeted Immunotherapy - GlobeNewswire
Annexon, Inc. (NASDAQ:ANNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-01-10 21:17:27 - Улправда
Is Annexon Inc. stock safe for conservative investorsJuly 2025 Catalysts & Long-Term Safe Return Strategies - ulpravda.ru
Is Annexon Inc. stock oversold or undervaluedMarket Growth Review & Risk Controlled Swing Trade Alerts - Улправда
Will Annexon Inc. stock beat EPS estimates2025 Pullback Review & Long-Term Growth Portfolio Plans - ulpravda.ru
Will Annexon Inc. stock continue upward momentumJuly 2025 Weekly Recap & Daily Momentum Trading Reports - Улправда
Institutional Investors Have a Lot Riding on Annexon, Inc. (NASDAQ:ANNX) With 68% Ownership - 富途牛牛
Annexon (ANNX) Seeks EMA Approval for Guillain-Barre Syndrome Dr - GuruFocus
Annexon Submits Tanruprubart Marketing Authorization Application To The European Medicines Agency For Guillain-Barré Syndrome - TradingView — Track All Markets
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome - manilatimes.net
Annexon Submits Tanruprubart Marketing Authorization - GlobeNewswire
Annexon Inc (ANNX) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):